Oric Pharmaceuticals Names Kevin Brodbeck as Chief Technical Officer

Oric Pharmaceuticals has appointed Kevin Brodbeck as its Chief Technical Officer (CTO), reflecting the advancement of its clinical programs into late-stage development with potential Phase 3 trials for ORIC-944 and enozertinib in 2026. Brodbeck brings over 25 years of experience in technical operations, quality assurance, and regulatory activities in pharmaceutical products. His appointment aligns with the company's growth in the pharmaceutical industry.

ORIC Pharmaceuticals (Nasdaq: ORIC) has appointed Kevin Brodbeck, PhD, as its first Chief Technical Officer (CTO), signaling a significant milestone in the company's transition towards late-stage clinical development. Dr. Brodbeck brings over 25 years of experience in technical operations, quality assurance, and regulatory activities, making him an ideal candidate to lead the company's technical operations as it prepares for potential Phase 3 trials in 2026.

The appointment of Dr. Brodbeck comes as ORIC prepares for the late-stage development of two key programs: ORIC-944 and enozertinib (ORIC-114). His background includes roles at Deciphera Pharmaceuticals and Nektar Therapeutics, where he led various development programs and managed global CMC operations. At Deciphera, he expanded Qinlock internationally and prepared Romvimza for regulatory approval in major markets. At Nektar, he led development programs across multiple therapeutic areas and stages, demonstrating his ability to navigate the complex technical requirements of late-stage clinical development and commercialization.

Dr. Brodbeck's appointment reflects ORIC's strategic planning to build infrastructure for manufacturing, quality control, and regulatory compliance required for registrational trials and beyond. This is critical for clinical-stage biotechs, as technical operations failures can lead to significant delays in the approval pathway even when clinical data is positive.

The creation of the CTO role and Dr. Brodbeck's appointment are part of ORIC's broader strategy to advance its clinical programs into late-stage development. The company has recently reported potentially best-in-class clinical efficacy and safety data from ongoing Phase 1b trials of ORIC-944 in combination with AR inhibitors for the treatment of patients with mCRPC. Additionally, ORIC has strengthened its cash position with $244 million in gross proceeds from top-tier healthcare specialist investors across $125 million in private placement financing and $119 million in ATM issuances.

ORIC's recent financing activity has also concluded its anticipated ATM facility usage, positioning the company to pursue its development plans and potential initiation of registrational trials in 2026 for ORIC-944 and enozertinib.

References:
[1] https://www.stocktitan.net/news/ORIC/oric-pharmaceuticals-expands-leadership-team-with-the-appointment-of-hmwv68829f6t.html
[2] https://www.biospace.com/press-releases/oric-pharmaceuticals-reports-second-quarter-2025-financial-results-and-operational-updates